Hernán Carol

4.4k total citations
93 papers, 3.0k citations indexed

About

Hernán Carol is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Hernán Carol has authored 93 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 29 papers in Neurology and 29 papers in Oncology. Recurrent topics in Hernán Carol's work include Neuroblastoma Research and Treatments (28 papers), Acute Lymphoblastic Leukemia research (19 papers) and Cancer therapeutics and mechanisms (11 papers). Hernán Carol is often cited by papers focused on Neuroblastoma Research and Treatments (28 papers), Acute Lymphoblastic Leukemia research (19 papers) and Cancer therapeutics and mechanisms (11 papers). Hernán Carol collaborates with scholars based in United States, Australia and Uruguay. Hernán Carol's co-authors include Richard B. Lock, Malcolm A. Smith, Peter J. Houghton, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, E. Anders Kolb, Richard Görlick, Christopher L. Morton and Min H. Kang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Hernán Carol

91 papers receiving 3.0k citations

Peers

Countries citing papers authored by Hernán Carol

Since Specialization

Citations

This map shows the geographic impact of Hernán Carol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hernán Carol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hernán Carol more than expected).

Fields of papers citing papers by Hernán Carol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hernán Carol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hernán Carol. The network helps show where Hernán Carol may publish in the future.

Co-authorship network of co-authors of Hernán Carol

This figure shows the co-authorship network connecting the top 25 collaborators of Hernán Carol. A scholar is included among the top collaborators of Hernán Carol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hernán Carol. Hernán Carol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) 2019 ·Clinical Cancer Research ·Yaël P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernán Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel	79
2	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL 2017 ·Clinical Cancer Research ·(unknown), Jennifer Richmond, Kathryn Evans, Hernán Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	17
3	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant 2016 ·Cancer Research ·Jennifer Richmond, Alissa K. Robbins, Kathryn Evans, Dominik Beck, Raushan T. Kurmasheva, Catherine A. Billups, Hernán Carol, Susan L. Heatley, Rosemary Sutton, Glenn M. Marshall, Deborah L. White, John E. Pimanda, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	18
4	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia 2016 ·Blood ·Seong Lin Khaw, Santi Suryani, Kathryn Evans, Jennifer Richmond, Alissa K. Robbins, Raushan T. Kurmasheva, Catherine A. Billups, Stephen W. Erickson, Yuelong Guo, Peter J. Houghton, Malcolm A. Smith, Hernán Carol, Andrew W. Roberts, David C.S. Huang, Richard B. Lock	112
5	Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia 2015 ·Clinical Cancer Research ·Jennifer Richmond, Hernán Carol, Kathryn Evans, (unknown), (unknown), Alissa K. Robbins, Claus Meyer, Nicola C. Venn, Rolf Marschalek, Michelle J. Henderson, Rosemary Sutton, Raushan T. Kurmasheva, Ursula R. Kees, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	41
6	Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia 2014 ·Molecular Cancer Therapeutics ·Santi Suryani, (unknown), Richard C. Harvey, (unknown), Hernán Carol, I‐Ming Chen, Kathryn Evans, (unknown), Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	43
7	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program 2014 ·Clinical Cancer Research ·Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton	90
8	The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia 2013 ·Clinical Cancer Research ·Hernán Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	57
9	Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 2011 ·PLoS ONE ·Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernán Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A. Zweidler‐McKay, Dario Campana, Gautam Borthakur, Carlos E. Bueso‐Ramos, Elizabeth J. Shpall, Deborah A. Thomas, Craig T. Jordan, Hagop M. Kantarjian, William R. Wilson, Richard B. Lock, Michael Andreeff, Marina Konopleva	98
10	Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program 2011 ·Pediatric Blood & Cancer ·Malcolm A. Smith, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, John M. Maris, Stephen T. Keir, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T. Kurmasheva, Peter J. Houghton	22
11	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program 2010 ·Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, (unknown), Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	79
12	Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program 2010 ·Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernán Carol, Richard B. Lock, Doris A. Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine A. Billups, Malcolm A. Smith	77
13	Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program 2010 ·Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, Christopher L. Morton, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine A. Billups, Malcolm A. Smith, Peter J. Houghton	60
14	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program 2009 ·Pediatric Blood & Cancer ·Richard Görlick, E. Anders Kolb, Peter J. Houghton, Christopher L. Morton, Doris A. Phelps, Paula Schaiquevich, Clinton F. Stewart, Stephen T. Keir, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Jianrong Wu, Malcolm A. Smith	26
15	Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886) 2008 ·Cancer Research ·Malcolm A. Smith, Christopher L. Morton, John M. Maris, Joshua Courtright, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Henry S. Friedman, Stephen T. Keir, Min H. Kang, C. Patrick Reynolds, Peter J. Houghton	1
16	Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton, John M. Maris, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernán Carol, Richard Görlick, E. Anders Kolb, (unknown), C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith	1
17	Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton, John M. Maris, Joshua Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernán Carol, Richard Görlick, E. Anders Kolb, Nino Keshelava, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith	1
18	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program 2007 ·Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	98
19	Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program 2007 ·Pediatric Blood & Cancer ·Richard B. Lock, Hernán Carol, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	99
20	A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms 1998 ·Veterinary Immunology and Immunopathology ·Hernán Carol, Alberto Nieto	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact